Expression of mos in ependymal gliomas

被引:8
作者
Athanasiou, A
Perunovic, B
Quilty, RD
Gorgoulis, VG
Kittas, C
Love, S
机构
[1] Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England
[2] Frenchay Hosp, Dept Neuropathol, Bristol BS16 1LE, Avon, England
[3] Univ Athens, Sch Med, Dept Histol & Embryol, GR-11527 Athens, Greece
关键词
ependymoma; brain neoplasms; c-mos; cell cycle; human; immunohistochemistry; proto-oncogene proteins;
D O I
10.1309/DL2TLDJG7JB1BQ72
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The c-mos gene and its protein product mos, components of the mitogen-activated protein kinase transduction pathway, are known to be involved in the control of meiosis and mitosis. Apart from our previous studies on lung carcinomas and astrocytic gliomas, little has been published about its role in human neoplasia. The aim of this study was to investigate the expression of mos in ependymal neoplasms and to correlate it with tumor grade, proliferative fraction, and clinical behavior. We studied mos expression in biopsy specimens from 34 patients with ependymomas. Intracytoplasmic immunopositivity for mos was found in 16 (47%) and was associated significantly with tumor grade: 5 (24%) of 21 grade II ependymomas; 11 (85%) of 13 grade III anaplastic ependymomas (P < .01). Tumors with an MIB-1 labeling index of more than 4% were significantly more likely than those with a lower proliferative fraction to be immunopositive for mos (P = .012). Eypression of mos showed a significant negative association with recurrence-free interval (P = .05) but not with overall survival. Our results suggest that overexpression of mos identifies a biologically aggressive subgroup of ependymal tumors and may be involved in their neoplastic progression.
引用
收藏
页码:699 / 705
页数:7
相关论文
共 37 条
[1]   c-mos immunoreactivity is an indicator of good prognosis in lung cancer [J].
Athanasiou, A ;
Gorgoulis, VG ;
Zacharatos, P ;
Mariatos, G ;
Kotsinas, A ;
Liloglou, T ;
Karameris, A ;
Foukas, P ;
Manolis, EN ;
Field, JK ;
Kittas, C .
HISTOPATHOLOGY, 2000, 37 (01) :45-54
[2]  
Bennetto L, 1998, NEUROPATH APPL NEURO, V24, P434
[3]  
BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504
[4]   CDKN2A/p16 in ependymomas [J].
Bortolotto, S ;
Chiadò-Piat, L ;
Cavalla, P ;
Bosone, I ;
Mauro, A ;
Schiffer, D .
JOURNAL OF NEURO-ONCOLOGY, 2001, 54 (01) :9-13
[5]   Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas [J].
de Foy, KAF ;
Gayther, SA ;
Colledge, WH ;
Crockett, S ;
Scott, IV ;
Evans, MJ ;
Ponder, BAJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (10) :1642-1644
[6]   Molecular genetic analysis of ependymal tumors - NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas [J].
Ebert, C ;
von Haken, M ;
Meyer-Puttlitz, B ;
Wiestler, OD ;
Reifenberger, G ;
Pietsch, T ;
von Deimling, A .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :627-632
[7]  
Fink KL, 1996, J NEURO-ONCOL, V27, P111
[8]   Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability [J].
Fukasawa, K ;
VandeWoude, GF .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (01) :506-518
[9]   MOS OVEREXPRESSION IN SWISS 3T3 CELLS INDUCES MEIOTIC-LIKE ALTERATIONS OF THE MITOTIC SPINDLE [J].
FUKASAWA, K ;
VANDEWOUDE, GF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3430-3434
[10]  
FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093